TCI Wealth Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

TCI Wealth Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-39	Closed	-$3.55K	–	2460
2023 Q1	$3.55K	Buy	+39	New	+$2.29K	﹤0.01%	1755
2022 Q3	–	Sell	-139	Closed	-$4K	–	2680
2022 Q2	$4K	Hold	139	–	–	﹤0.01%	1733
2022 Q1	$5K	Hold	139	–	–	﹤0.01%	1634
2021 Q4	$4K	Buy	139 +81	+140%	+$6.27K	﹤0.01%	1950
2021 Q3	$6K	Buy	58 +28	+93%	+$3.28K	﹤0.01%	1536
2021 Q2	$4K	Buy	+30	New	+$3.39K	﹤0.01%	1671
2021 Q1	–	Sell	-11	Closed	-$1K	–	2263
2020 Q4	$1K	Buy	+11	New	+$1.45K	﹤0.01%	1495

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCI Wealth Advisors's RETA Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 39 shares — an estimated $3.55K sold.

TCI Wealth Advisors first reported a position in RETA in Q4 2020 and held it in 7 quarters. The position peaked at $6K in Q3 2021. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

TCI Wealth Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 39 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $3.55K.
TCI Wealth Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 7 quarters.
TCI Wealth Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $6K in Q3 2021.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.